21:42 , Jul 3, 2019 |  BC Extra  |  Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Shiyu Capital leads Lepu’s $131M A round  Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing...
00:51 , Jun 7, 2019 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
21:22 , May 15, 2019 |  BC Extra  |  Company News

Takeda veterans, Frazier launch Phathom with $90M to develop GI drug vonoprazan

Marking the partners' second company launch with a Takeda-discovered asset, Frazier Healthcare Partners and the Japanese pharma launched Phathom with rights to gastrointestinal drug vonoprazan. The start-up, which will focus on developing treatments for acid-related...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
10:30 , Apr 1, 2019 |  BC Extra  |  Financial News

SpringWorks raises $125M series B round

A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to...
23:43 , Mar 27, 2019 |  BC Extra  |  Financial News

Gene therapy company Prevail raises $50M series B

Prevail raised $50 million in a series B round to advance its pipeline of gene therapies for neurodegenerative diseases. Existing investors participating in the round included OrbiMed Advisors, Pontifax, RA Capital Management, EcoR1 Capital, Omega...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Relay runs away with $400M series C on back of protein conformation platform

Protein motion company Relay Therapeutics Inc. (Cambridge, Mass.) raised $400 million on Dec. 20 in an untranched series C led by new investor SoftBank Vision Fund. Relay President and CEO Sanjiv Patel told BioCentury the...
12:00 , Dec 20, 2018 |  BC Extra  |  Financial News

Relay runs away with $400M series C on back of protein conformation platform

Protein motion company Relay Therapeutics Inc. (Cambridge, Mass.) raised $400 million in an untranched series C led by new investor SoftBank Vision Fund. Relay President and CEO Sanjiv Patel told BioCentury the round will provide...
19:11 , Dec 14, 2018 |  BC Week In Review  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...